Overview
Eli Lilly reported that an experimental drug, retatrutide, led to an average body weight reduction of 28 percent in individuals who received the injection. This outcome was observed over an 80-week period.
Retratrutide Administration Associated with Substantial Body Weight Reduction
Read research and analysis on Retratrutide Administration Associated with Substantial Body Weight Reduction published by ICANEWS, a global research journal for emerging researchers.
Key Takeaways
- Participants receiving retatrutide injections experienced an average body weight loss of 28 percent.
- The body weight reduction was observed over an 80-week duration.
- The findings were reported by Eli Lilly regarding the experimental drug retatrutide.
Research Information
- Institution
- Eli Lilly
- Original Study
- View Publication
- Source
- NY Times Science
About ICANEWS
ICANEWS is a global research journal for emerging researchers, publishing student and emerging researcher work across all fields.